Skip to main content
Premium Trial:

Request an Annual Quote

A Personal Effort

Stanford University's Ron Davis has become focused on helping people with myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS), CNN reports. It writes that the work is personal for him, as his son has a severe form of the condition and needs the care of Davis and his wife, Janet Dafoe.

"It has turned my life upside down in many respects. I decided to terminate everything I was working on before Whitney got sick," Davis tells CNN. "Everything is ME/CFS now. It's an emergency kind of effort."

The Open Medicine Foundation — Davis directs its scientific advisory board — committed $1.2 million toward a ME/CFS Collaborative Research Center at Stanford in 2017, as GenomeWeb reported at the time. CNN adds that OMF has raised $18 million to study the disease. It further notes that Davis and his colleagues are analyzing blood from Davis' son and other patients using a nanoneedle they developed. They hope, it says, to tease out a biomarker for the disease, which they say would help the condition be better recognized and help drug companies develop treatments.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.